CAS: 670220-88-9; 1-[2-[5-[(3-Methyl-3-Oxetanyl)Methoxy]-1-Benzimidazolyl]-8-Quinolyl]-4-Piperidinamine

上下游产品

CAS号670220-93-6 Crenolanib

📜1H-苯并咪唑-5-醇置于sodium Ethanolate,Palladium Diacetate,Sodium,Potassium Carbonate,1,2-双(二苯基膦)乙烷体系中,用 四氢呋喃,2-甲基四氢呋喃,水,甲苯 作为反应溶剂,化学反应 4.0H,反应生成 [1-[2-[5-(3-甲基氧杂环丁烷-3-基甲氧基)苯并咪唑-1-基]喹啉-8-基]哌啶-4-基]胺
参考文献:一种治疗白血病药物的制备方法
标题:一种治疗白血病药物的制备方法
摘要:本发明涉及一种治疗白血病药物的制备方法,该方法包括以下步骤,步骤1:2‑氯‑8‑三氟甲磺酸基喹啉的制备步骤2:2‑氯‑8(哌啶‑4基)喹啉氨基甲酸叔丁酯的制备步骤3:5‑(3‑甲基氧杂环丁烷‑3‑甲氧基)苯并咪唑的制备步骤4:(1‑{2‑[5‑(3‑甲基‑氧杂环丁烷‑3‑基甲氧基)‑苯并咪唑‑1‑基]‑喹啉‑8‑基}‑哌啶‑4‑基‑氨基甲酸叔丁酯的制步骤5:(1‑{2‑[5‑(3‑甲基‑氧杂环丁烷‑3‑基甲氧基)‑苯并咪唑‑1‑基]‑喹啉‑8‑基}‑4‑氨基哌啶的制备.

专利信息

专利号:WO-2024132278-A1
优先权日:2022-12-20
标题:Synthesis, pharmacology and use of new water-soluble and selective fms-like tyrosine kinase 3 (flt3) inhibitors
发明人：MAHBOOBI SAVOSH; WIRTH LUKAS; PONGARTZ HERWIG; SELLMER ANDREAS
权利人:UNIV REGENSBURG
摘要:The present application relates to compounds of formula (I) for inhibiting FLT3. The present application further relates to a composition, preferably pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt thereof and comprising a pharmaceutically acceptable excipient and/or carrier. The present application also relates to a compound or composition for use in medicine. The present application also relates to a compound or composition for use in a method of preventing or treating cancer, preferably blood cancer, more preferably leukemia, even more preferably acute myeloid leukemia (AML). Furthermore, the present application relates to a method of preparing a compound.

专利号:US-11384076-B2
优先权日:2017-08-18
标 题:Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors
发明人：MAHBOOBI SIAVOSH; SELLMER ANDREAS; PONGRATZ HERWIG; PILSL BERNARDETTE; KRÄMER OLIVER; KINDLER THOMAS; BEYER MANDY
权利人:UNIV REGENSBURG; UNIV DER JOHANNES GUTENBERG UNIV MAINZ
摘要:The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.

专利号:US-2022411407-A1
优先权日:2019-11-15
标题:Aryl aminopyrimidines as dual mertk and tyro3 inhibitors and methods thereof
发明人：WANG XIAODONG; ZHOU YUBAI; DING RANSHENG; KONG DEYU; FRYE STEPHEN
权利人:UNIV NORTH CAROLINA CHAPEL HILL
摘要:Aminopyrimidine containing compounds that inhibit both Mer tyrosine kinase (MerTK) activity and Tyro3 kinase activity are disclosed herein. Additionally disclosed are methods of synthesis and use of the aminopyrimidine containing compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents.

专利号:CN-107382983-A
优先权日:2017-08-24
标题:A kind of synthesis method of medicine for treating leukemia

专利号:EP-4389223-A1
优先权日:2022-12-20
标 题 :Synthesis, pharmacology and use of new water-soluble and selective fms-like tyrosine kinase 3 (flt3) inhibitors